Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining
potent anticancer activity, are of particular interest. Agents which can modulate multiple …

Present studies demonstrate that treatment with the histone deacetylases inhibitor LAQ824,
a cinnamic acid hydroxamate, increased the acetylation of histones H3 and H4, as well as …

Cancer is a multi-factorial process involving genetic and epigenetic events which result in
neoplastic transformation. Reversal of aberrant epigenetic events, including those that …

Histone deacetylase (HDAC) inhibitors induce differentiation and/or apoptosis in a variety of
cell types by activating transcription of target genes. Activation of the death receptor (DR) …

Histone deacetylase inhibitors (HDACIs) inhibit the growth of a variety of transformed cells in
culture. We demonstrated previously that the hybrid-polar HDACI m-carboxycinnamic acid …

Histone deacetylase inhibitors (HDACi) are a promising new class of chemotherapeutic drug
currently in early phase clinical trials. A large number of structurally diverse HDACi have …

Abstract Background Histone deacetylase inhibitors (HDACIs) induce hyperacetylation of
core histones modulating chromatin structure and affecting gene expression. These …

Alzheimer's disease (AD) is the most important neurodegenerative disorder in Western
countries. Pathological phenotypes of neurodegeneration result from a combination of …

The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase
Bcr-Abl. Imatinib mesylate (also known as STI-571 and Gleevec), a tyrosine kinase inhibitor …

Histone deacetylases (HDACs) have recently emerged as an important target for therapeutic
intervention in cancer and potentially other human diseases. By modulating the acetylation …